Unknown

Dataset Information

0

RBD-Modified Bacterial Vesicles Elicited Potential Protective Immunity against SARS-CoV-2.

ABSTRACT: The disease caused by SARS-CoV-2 infection threatens human health. In this study, we used high-pressure homogenization technology not only to efficiently drive the bacterial membrane to produce artificial vesicles but also to force the fusion protein ClyA-receptor binding domain (RBD) to pass through gaps in the bacterial membrane to increase the contact between ClyA-RBD and the membrane. Therefore, the load of ClyA-RBD on the membrane is substantially increased. Using this technology, we constructed a "ring-like" bacterial biomimetic vesicle (BBV) loaded with polymerized RBD (RBD-BBV). RBD-BBVs injected subcutaneously can accumulate in lymph nodes, promote antigen uptake and processing, and elicit SARS-CoV-2-specific humoral and cellular immune responses in mice. In conclusion, we evaluated the potential of this novel bacterial vesicle as a vaccine delivery system and provided a new idea for the development of SARS-CoV-2 vaccines.

SUBMITTER: Yang Z 

PROVIDER: S-EPMC8315139 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

The disease caused by SARS-CoV-2 infection threatens human health. In this study, we used high-pressure homogenization technology not only to efficiently drive the bacterial membrane to produce artificial vesicles but also to force the fusion protein ClyA-receptor binding domain (RBD) to pass through gaps in the bacterial membrane to increase the contact between ClyA-RBD and the membrane. Therefore, the load of ClyA-RBD on the membrane is substantially increased. Using this technology, we constr  ...[more]

Similar Datasets

Unknown Lyophilized, thermostable Spike or RBD immunogenic liposomes induce protective immunity against SARS-CoV-2 in mice.
| S-EPMC8635435 | biostudies-literature
Unknown Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse.
| S-EPMC7934688 | biostudies-literature
Unknown RBD-displaying OMV nanovaccine boosts immunity against SARS-CoV-2.
| S-EPMC11807311 | biostudies-literature
Unknown Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein.
| S-EPMC8578532 | biostudies-literature
Unknown An RBD-Based Diagnostic Method Useful for the Surveillance of Protective Immunity against SARS-CoV-2 in the Population.
| S-EPMC9324632 | biostudies-literature
Unknown Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2.
| S-EPMC8280646 | biostudies-literature
Unknown Amantadine-assembled nanostimulator enhances dimeric RBD antigen-elicited cross-neutralization against SARS-CoV-2 strains.
| S-EPMC8752318 | biostudies-literature
Unknown Genetic Variants and Protective Immunity against SARS-CoV-2.
| S-EPMC9778397 | biostudies-literature
Unknown Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection.
| S-EPMC8372230 | biostudies-literature
Unknown The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice.
| S-EPMC8426336 | biostudies-literature